Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
JIANGSU, China--(BUSINESS WIRE)--Jan 2, 2024--
Stay updated with breaking news from Atom Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JIANGSU, China--(BUSINESS WIRE)--Jan 2, 2024--
Take a closer look at 10 Asia-Pacific companies leading innovation in the biotech and biopharma industry in the region.
Biopharmaceutical firm Jiangsu Atom Bioscience and Pharmaceutical has bagged 600 million yuan ($82.8 million) in a Series D funding round.
ABP-671 effective at lowering serum uric acid, the cause of gout JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today that it will present final dated data from its Phase 2a clinical trial of its s...
Press release content from Business Wire. The AP news staff was not involved in its creation.